Changes in antibiotic usage and susceptibility in nosocomial Enterobacteriaceae and Pseudomonas isolates following the introduction of ertapenem to hospital formulary

Epidemiology and Infection

Volumn 140, Issue 1, 2012, Pages 115-125

  Graber, C J ^a,b   Hutchings, C ^a   Dong, F ^a   Lee, W ^c   Chung, J K ^d   Tran, T ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antibiotic resistance; antibiotics; hospital microbiology; hospital acquired (nosocomial) infections; Pseudomonas

Indexed keywords

CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG USE; ENTEROBACTERIACEAE; HOSPITAL INFECTION; NONHUMAN; PSEUDOMONAS; TIME SERIES ANALYSIS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CROSS INFECTION; DRUG PRESCRIPTIONS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; HUMANS; PSEUDOMONAS; REGRESSION ANALYSIS;

EID: 82455192328     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268811000082     Document Type: Article

References (13)

1. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. Journal of Antimicrobial Chemotherapy 2003; 52: 331-344. (Pubitemid 37120709)
2. Merck & Company, Incorporated. Invanz product insert. (http://www.merck.com/product/usa/pi-circulars/i/invanz/invanz-pi.pdf). Accessed 1 November 2010.
3. Livermore DM, Mushtaq S, Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants crossresistant to other carbapenems. Journal of Antimicrobial Chemotherapy 2005; 55: 306-311. (Pubitemid 40425453)
4. DiNubile MJ, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. European Journal of Clinical Microbiology and Infectious Diseases 2005; 24: 443-449.
5. Goff DA, Mangino JE. Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. Journal of Infection 2008; 57: 123-127.
6. Lima AL, et al. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infection Control and Hospital Epidemiology 2009; 30: 487-490.
7. Goldstein EJ, et al. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2009; 53: 5122-5126.
8. Eagye KJ, Nicolau DP. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infection Control and Hospital Epidemiology 2010; 31: 485-490.
9. Shardell M, et al. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clinical Infectious Diseases 2007; 45: 901-907. (Pubitemid 47580386)
10. Zeger SL, Irizarry R, Peng RD. On time series analysis of public health and biomedical data. Annual Review of Public Health 2006; 27: 57-79.
11. Bosso JA, Mauldin PD. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2006; 50: 2106-2112. (Pubitemid 43807532)
12. WHO Collaborating Centre for Drug Statistics Methodology. Defined daily dose: definition and general considerations (http://www.whocc.no/ddd/definition- and-general-considera/). Accessed 1 November 2010.
13. Polk RE, et al. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clinical Infectious Diseases 2007; 44: 664-670.